3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Personality Disorder, Schizoid in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abi-Dargham, A; Cooper, T; Kegeles, LS; Koenigsberg, HW; Laruelle, M; Martinez, D; Mawlawi, O; Mitropoulou, V; O'Flynn, K; Siever, LJ; Van Heertum, R; Zea-Ponce, Y | 1 |
1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Personality Disorder, Schizoid
Article | Year |
---|---|
Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide.
Topics: Adult; Amphetamine; Analysis of Variance; Benzamides; Case-Control Studies; Central Nervous System Stimulants; Corpus Striatum; Dopamine; Dopamine Antagonists; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Schizoid Personality Disorder; Tomography, Emission-Computed, Single-Photon | 2004 |